“Microbiology: the future of medicine!” Have you ever thought about it? Right here in Lyon stands Bioaster Microbiology Technology Institute. It is a hub of innovation. Bioaster is dedicated to tackling the world’s toughest challenges in microbiology.
Founded in 2012, Bioaster operates as a non-profit technological research institute. The French government initiated it. Bioaster is committed to collaborative research. It works with both public and private partners. Its mission? To drive advancements in key areas. These areas include vaccines, antimicrobials, diagnostics, and understanding the human microbiota.
Step inside Bioaster. You will find a team of over 100 employees from 17 nationalities. Eighty percent of them are scientific experts. They work in state-of-the-art laboratories in Lyon and Paris. These include biosafety level 2 and 3 labs. Bioaster boasts more than 250 research contracts. These involve 93 private and 54 public partners.
Bioaster’s model is unique. It brings together academic knowledge and industrial capabilities. This fosters high-impact collaborative projects. These projects require industry-compatible innovative technologies.
Bioaster focuses on four fields of expertise. These are antimicrobials, diagnostics, microbiome, and vaccines. The institute develops high-value technological innovations. They accelerate medical solutions for populations. Bioaster also develops solutions for personalized medicine.
One key area is metabolomics and proteomics. Bioaster’s unit focuses on identifying biomarkers. They work to functionally characterize metabolic pathways. This applies to the R&D of antimicrobials, vaccines, diagnostic tests, and probiotics. The unit uses metabolic profiling and quantitative metabolomics. Mass Spectrometry Imaging is used too.
Bioaster also plays a role in larger research initiatives. It participates in projects like TRANSVAC. Here, they contribute to immuno-correlates and systems biology.
In 2020, Evotec partnered with Bioaster. Together, they built a technology and innovation hub in Lyon. This partnership accelerates research into infectious diseases. It also combats antimicrobial resistance. The collaboration strengthens the research ecosystem. It provides a more powerful technological toolbox. This speeds up the industrialization of innovations.
Dr. Philippe Archinard, President of IRT BIOASTER, is proud of Bioaster’s network. It includes French and European leaders in diagnostics and vaccines. Dr. Werner Lanthaler, CEO of Evotec, also shows his enthusiasm. Evotec brings its global resources for anti-infective research to Lyon.
Bioaster strengthens its technological agility through partnerships. This allows it to better address antimicrobial resistance. The institute’s location fosters collaboration. Evotec and Bioaster share advanced infrastructures. This includes five BSL3 laboratories. This close proximity benefits industrial partners. It accelerates their product development. It also reduces risks in infectious diseases.
As you stand before Bioaster, consider its impact. Bioaster is not just a building. It’s a driving force in microbiology. It brings together diverse experts. It fosters innovation and accelerates solutions. Bioaster improves global health. Its work impacts manufacturers and patients alike.